<DOC>
	<DOCNO>NCT01772264</DOCNO>
	<brief_summary>The notable tolerability find multiple dose study occurrence mild moderate rash dose 450 mg BID 600 mg BID . Based upon find , current four week study design examine whether slow titration regimen low maintenance dose 450 mg BID able reduce incidence rash .</brief_summary>
	<brief_title>Safety And Tolerability Study Of BID Titration Scheme With PF-05089771</brief_title>
	<detailed_description />
	<criteria>Healthy male and/or female subject nonchild bear potential age 18 55 year , inclusive ( Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate Evidence history clinically significant hematological , renal ( ie , recurrent nephrolitisis ) , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . History , presence allergic skin reaction active skin disease ( except subject acne may include study ) time screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>